Generation of In-Frame Gene Deletion Mutants in Pseudomonas aeruginosa and Testing for Virulence Attenuation in a Simple Mouse Model of Infection

Executive Industry Relevance

This protocol enables the generation of attenuated Pseudomonas aeruginosa strains for biopharmaceutical production, offering a potential alternative to E. coli in cases where product yields are suboptimal. By creating marker-free, virulence-attenuated strains through sequential genomic deletions, the method supports early-stage target validation and mechanistic de-risking for antimicrobial or enzyme production pathways. The reproducible mouse infection model provides a standardized assay to evaluate attenuation, facilitating go/no-go decisions in strain selection for industrial applications.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of gene function through in-frame deletions to assess virulence factor contributions.
• Operational Value: Produces marker-free strains avoiding antibiotic resistance markers that could complicate industrial use.
• Predictive Value: Supports phenotypic screening of attenuation via murine infection models to prioritize targets with reduced pathogenicity.

Screening & Assay Development

• Scientific Value: Colony PCR and agarose gel electrophoresis provide quantitative readouts for deletion validation.
• Operational Value: Standardized sucrose selection and carbenicillin sensitivity screening ensure reproducibility across mutant libraries.
• Assay Readiness: Cryopreserved stocks allow batch preparation and consistent inoculum preparation for downstream testing.

Translational & Preclinical Research

• Disease Relevance: The murine systemic infection model mirrors host-pathogen interactions relevant to virulence assessment.
• Translational Continuity: Attenuated strains showing 0% mortality in mice align with safety thresholds for industrial strain deployment.
• Risk Mitigation: Comparing attenuation to FDA-approved E. coli BL21 provides a benchmark for evaluating strain suitability in production settings.

Pipeline & Workflow Integration

The method fits within the discovery-to-preclinical continuum by linking genetic engineering to functional validation in a host model, supporting iterative strain optimization.

• Discovery Biology: Gene deletion mutants allow hypothesis testing of virulence mechanisms and pathway essentiality.
• Screening: Sucrose-resistant, carbenicillin-sensitive screening enables scalable identification of double crossover recombinants.
• Analytics: Colony PCR with size-shift detection provides a binary output for deletion confirmation, enabling high-throughput genotyping.
• Translational Research: Murine infection model connects genetic modifications to phenotypic outcomes in a disease-relevant system.
• Enterprise Reuse: The pEX100T-NotI plasmid system and infection protocol can be adapted to other Gram-negative pathogens for strain attenuation projects.

Operational & Enterprise Impact

• Scientific Value: Mechanistic de-risking of virulence factors through defined genetic deletions.
• Operational Value: Reproducible mouse model and standardized bacterial preparation reduce variability in attenuation testing.
• Strategic Value: Enables risk-adjusted prioritization of strains for production based on virulence attenuation data.
• Portfolio Impact: Supports go/no-go decisions by comparing test strains to a validated non-pathogenic control (E. coli BL21).

Implementation Considerations

• Requires expertise in molecular cloning, allele exchange, and murine handling techniques.
• Dependent on access to anaerobic workstations, PCR equipment, and biosafety level 2 animal facilities.
• Standardization across labs necessitates synchronized use of PIA plates, sucrose selection, and cryovial thawing protocols.
• Adaptation to other pathogens may require optimization of selection markers and infection routes.
• Practical limitations include the time-intensive nature of sequential deletions and the need for phenotypic validation beyond mortality, such as bioluminescence tracking.

Biopharma FAQs